Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
When considering tamoxifen for a DCIS diagnosis, according to the study linked and excerpted below, less is more. While a diagnosis of DCIS is pre-breast cancer and not frank brest cancer, newly diagnosed patients may worry about the risk of relapse. But because DCIS has a 10 year survival rate that is so high, it may be difficult to justify years of serious adverse events aka side effects.
The solution? Low-dose tamoxifen- 5 mg daily for three years instead of 20 mg daily for five years. According to the article below, the efficacy or reduced risk of relapse is the same but the risk of “adverse events” are greatly reduced.
Anytime a person can achieve the same benefit but with less toxicity, the choice is clear.
I am not a DCIS survivor. I am a long-term survivor of a very different cancer called multiple myeloma. My interest in writing this blog post is a concept that I live with and write about frequently. I live with extensive long-term and late stage side effects that could have been moderated or eliminated completely by lowering the dose of my conventonal chemotherapy.
When I find a study liked the one below, I rush to write about less toxic chemotherapy being just as effective as higher dose chemotherapy but without the degree of adverse events (side effects).
Do you know the real kicker? There are a host of evidence-based non-toxic therapies that have been shown to also reduce the risk of a breast cancer diagnosis after a DCIS diagnosis.
To learn more about DCIS and the evidence-based therapies that can help you prevent its spread into invasive breast cancer, please watch the video below:
Have you been diagnosed with Ductal Carcinoma In-Situ? Please scroll down the page, post a question or comment and I will reply to you ASAP.
” We observed that green tea increased the inhibitory effect of tamoxifen on the proliferation of the ER (estrogen receptor)-positive MCF-7, ZR75, T47D human breast cancer cells in vitro. This combination regimen was also more potent than either agent alone at increasing cell apoptosis…”
“Daily use of low-dose (5 mg) tamoxifen (multiple brands) for a shorter-than-usual treatment period (3 years) for patients with ductal carcinoma in situ (DCIS) and other forms of noninvasive breast cancer halved the recurrence of new breast cancer events in comparison with placebo, a new Italian study indicates…
Tamoxifen is typically prescribed post surgery at a dosage of 20 mg/day for 5 years for DCIS and these other conditions… Tamoxifen was developed in the 1960s, but the minimal effective dose has never been established…
In the new 500-patient trial, 5.5% patients in the low-dose tamoxifen arm had either experienced disesase recurrence or had new disease, including invasive disease, compared with 11.3% in the placebo arm…
“When we compare our low-dose tamoxifen data with results from the NSABP B-24 and NSABP-P1 trials of tamoxifen given at 20 mg per day, we see comparable risk reduction and significantly reduced serious adverse events, respectively,” said De Censi in a press statement at the meeting…”
Tamoxifen has also been shown to increase the incidence of deep vein thrombosis, pulmonary embolism, and cataracts.1,21 Both deep vein thrombosis and pulmonary embolism pose significant health risks, and can lead to heart attacks, ischemic stroke, and death…